Pramipexole use and the risk of pneumonia

BMC Neurology

Table 2 Crude and adjusted rate ratios of pneumonia associated with current use of pramipexole relative to other dopamine agonists

	Cases	Controls	Crude	Adjusted*
	Cases	Controls	Rate Ratio	Rate ratio	95% CI
Number of subjects	1835	16,088
Current use† of (%)
Pramipexole (%)	59 (3.2)	734 (4.6)	0.80	0.85	0.62 – 1.17
All other dopamine agonists (%)	210 (11.4)	2112 (13.1)	1.00	1.00	Reference
Pramipexole (%)	59 (3.2)	734 (4.6)	0.90	0.95	0.68 – 1.35
Non-Ergot-derived dopamine agonists (%)	101 (5.5)	1157 (7.2)	1.00	1.00	Reference
Pramipexole (%)	59 (3.2)	734 (4.6)	0.72	0.75	0.53 – 1.08
Ergot-derived dopamine agonists (%)	109 (5.9)	966 (6.0)	1.00	1.00	Reference

* Adjusted for current use of other anti-parkinsonian drugs, including levodopa, selegiline, rasagiline, COMT inhibitors and amantadine, and all factors listed in Table 1.
† Current use refers to a prescription ending after or within 30 days prior to the index date.

ISSN: 1471-2377